
|Articles|July 1, 2003
Novel Nanoparticle Formulation Fights SCC
Chicago - A novel nanoparticle formulation of paclitaxel (ABI-007) administered intra-arterially has been shown to be well tolerated and very active against squamous carcinomas of the head and neck, uterus, and anal canal, Bruno Damascelli, M.D., said at the 39th annual meeting of the American Society of Clinical Oncology.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5

















